Postinflammatory hyperpigmentation
Postinflammatory hyperpigmentation yra odos būklė, kuriai būdingas pigmento padidėjimas odoje po odos uždegimo. Postinflammatory hyperpigmentation gali atsirasti dėl ilgalaikio buvimo saulėje, uždegimo ar kitų odos sužalojimų, įskaitant susijusius su spuogais. Žmonės su tamsesniu odos atspalviu paprastai yra labiau linkę į hiperpigmentaciją dėl pernelyg didelio saulės poveikio.
☆ 2022 m. Stiftung Warentest iš Vokietijos rezultatai rodo, kad vartotojų pasitenkinimas ModelDerm buvo tik šiek tiek mažesnis nei mokamų nuotolinės medicinos konsultacijų.
References
Postinflammatory hyperpigmentation (PIH) yra dažna odos problema, kuri atsiranda po odos uždegimo ar sužalojimo. Jis paprastai trunka ilgai ir yra blogesnis žmonėms, kurių odos atspalvis tamsesnis (Fitzpatrick skin types III–VI) . Nors dažnai pagerėja savaime, tai gali užtrukti, todėl gydymo dažnai prireikia ilgai. Geriausiai veikia skirtingų gydymo būdų derinimas.
Postinflammatory hyperpigmentation (PIH) is a common acquired cutaneous disorder occurring after skin inflammation or injury. It is chronic and is more common and severe in darker-skinned individuals (Fitzpatrick skin types III–VI). While the condition typically improves spontaneously, this process can take months to years, necessitating prolonged treatment. Combination therapy is the most effective.
Postinflammatory hyperpigmentation (PIH) is a common acquired cutaneous disorder occurring after skin inflammation or injury. It is chronic and is more common and severe in darker-skinned individuals (Fitzpatrick skin types III–VI). While the condition typically improves spontaneously, this process can take months to years, necessitating prolonged treatment. Combination therapy is the most effective.
Postinflammatory hyperpigmentation yra dažna odos uždegimo pasekmė. Ji linkusi smarkiau ir dažniau paveikti tamsesnės odos žmones. Tyrimai rodo, kad tokios problemos kaip postinflammatory hyperpigmentation yra viena iš pagrindinių priežasčių, kodėl tamsesnio odos atspalvio žmonės kreipiasi į dermatologinę priežiūrą. Ankstyvas gydymas yra labai svarbus norint išspręsti postinflammatory hyperpigmentation ir paprastai prasideda nuo pradinės uždegiminės būklės valdymo. Pirmoji gydymo linija paprastai apima vietinių priemonių, kurios šviesina odą, naudojimą kartu su apsaugos nuo saulės priemonėmis. Šios priemonės, tokios kaip hydroquinone, azelaic acid, kojic acid, arbutin, licorice extracts , gali veiksmingai sumažinti pernelyg didelę pigmentaciją. Be to, retinoids, mequinol, ascorbic acid, niacinamide, N-acetyl glucosamine, soy taip pat naudojami kaip depigmentuojančios medžiagos, atsiranda naujų gydymo būdų. Nors vietinis gydymas paprastai yra veiksmingas esant paviršiaus hiperpigmentacijai, procedūrų (laser, chemical peel) gali prireikti sunkiais atvejais. Svarbu atsargiai naudoti šiuos gydymo būdus, kad išvengtumėte dirginimo ir postinflammatory hyperpigmentation pablogėjimo.
Postinflammatory hyperpigmentation is a common sequelae of inflammatory dermatoses that tends to affect darker skinned patients with greater frequency and severity. Epidemiological studies show that dyschromias, including postinflammatory hyperpigmentation, are among the most common reasons darker racial/ethnic groups seek the care of a dermatologist. The treatment of postinflammatory hyperpigmentation should be started early to help hasten its resolution and begins with management of the initial inflammatory condition. First-line therapy typically consists of topical depigmenting agents in addition to photoprotection including a sunscreen. Topical tyrosinase inhibitors, such as hydroquinone, azelaic acid, kojic acid, arbutin, and certain licorice extracts, can effectively lighten areas of hypermelanosis. Other depigmenting agents include retinoids, mequinol, ascorbic acid, niacinamide, N-acetyl glucosamine, and soy with a number of emerging therapies on the horizon. Topical therapy is typically effective for epidermal postinflammatory hyperpigmentation; however, certain procedures, such as chemical peeling and laser therapy, may help treat recalcitrant hyperpigmentation. It is also important to use caution with all of the above treatments to prevent irritation and worsening of postinflammatory hyperpigmentation.
Postinflammatory hyperpigmentation is a common sequelae of inflammatory dermatoses that tends to affect darker skinned patients with greater frequency and severity. Epidemiological studies show that dyschromias, including postinflammatory hyperpigmentation, are among the most common reasons darker racial/ethnic groups seek the care of a dermatologist. The treatment of postinflammatory hyperpigmentation should be started early to help hasten its resolution and begins with management of the initial inflammatory condition. First-line therapy typically consists of topical depigmenting agents in addition to photoprotection including a sunscreen. Topical tyrosinase inhibitors, such as hydroquinone, azelaic acid, kojic acid, arbutin, and certain licorice extracts, can effectively lighten areas of hypermelanosis. Other depigmenting agents include retinoids, mequinol, ascorbic acid, niacinamide, N-acetyl glucosamine, and soy with a number of emerging therapies on the horizon. Topical therapy is typically effective for epidermal postinflammatory hyperpigmentation; however, certain procedures, such as chemical peeling and laser therapy, may help treat recalcitrant hyperpigmentation. It is also important to use caution with all of the above treatments to prevent irritation and worsening of postinflammatory hyperpigmentation.
